QIAGEN (QGEN)
(Real Time Quote from BATS)
$41.92 USD
+0.37 (0.89%)
Updated Jul 22, 2024 11:06 AM ET
2-Buy of 5 2
C Value D Growth B Momentum C VGM
Qiagen (QGEN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$51.36 | $60.00 | $45.00 | 23.61% |
Price Target
Based on short-term price targets offered by 12 analysts, the average price target for Qiagen comes to $51.36. The forecasts range from a low of $45.00 to a high of $60.00. The average price target represents an increase of 23.61% from the last closing price of $41.55.
Analyst Price Targets (12)
Broker Rating
Qiagen currently has an average brokerage recommendation (ABR) of 1.75 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 14 brokerage firms. The current ABR compares to an ABR of 1.89 a month ago based on 14 recommendations.
Of the 14 recommendations deriving the current ABR, eight are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 57.14% and 7.14% of all recommendations. A month ago, Strong Buy made up 50%, while Buy represented 7.14%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/QGEN.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 7 | 7 | 7 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 5 | 5 | 6 | 6 | 6 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.75 | 1.75 | 1.89 | 1.89 | 1.89 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/27/2024 | Not Identified | Not Identified | Hold | Strong Buy |
6/18/2024 | UBS | John N Sourbeer | Hold | Hold |
5/1/2024 | Not Identified | Not Identified | Hold | Hold |
5/1/2024 | William Blair | Andrew F Brackmann | Hold | Hold |
4/1/2024 | Cowen & Co. | Daniel Brennan | Hold | Hold |
2/8/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1/29/2024 | Robert W. Baird & Co. | Catherine W Schulte | Strong Buy | Strong Buy |
1/18/2024 | Berenberg Bank | Odysseas Manesiotis | Not Available | Strong Buy |
1/3/2024 | Not Identified | Not Identified | Hold | Hold |
12/7/2023 | Goldman Sachs | Matthew Sykes | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.75 |
ABR (Last week) | 1.75 |
# of Recs in ABR | 14 |
Average Target Price | $51.36 |
LT Growth Rate | 6.10% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 71 of 252 |
Current Quarter EPS Est: | 0.52 |